These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21597288)

  • 1. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
    Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
    Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
    Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
    Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].
    Muneoka K; Shirai Y; Sasaki M; Wakai T; Sakata J; Toshima M; Hatakeyama K
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):61-4. PubMed ID: 18195529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
    Endlicher E; Schnoy E; Troppmann M; Rogler G; Messmann H; Klebl F; Gelbmann C; Kullmann F
    Digestion; 2016; 93(3):229-33. PubMed ID: 27089254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
    Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
    Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
    Larsen FO; Markussen A; Diness LV; Nielsen D
    Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
    Kanai M; Yoshimura K; Tsumura T; Asada M; Suzuki C; Niimi M; Matsumoto S; Nishimura T; Nitta T; Yasuchika K; Taura K; Mori Y; Hamada A; Inoue N; Tada S; Yanagihara K; Yazumi S; Osaki Y; Chiba T; Ikai I; Fukushima M; Uemoto S; Hatano E
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1429-34. PubMed ID: 20811895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K
    Invest New Drugs; 2011 Dec; 29(6):1488-93. PubMed ID: 20607585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.